About this Research Topic
Cardiovascular diseases, such as coronary heart disease, heart failure, hypertension, stroke, and myocardial infarction, are intimately linked to the aging process. Age-related decline in immune system function, known as immunosenescence, plays a critical role in the onset and progression of these diseases. Additionally, chronic inflammation, a hallmark of immunological aging, contributes to organ damage and the development of age-associated cardiovascular diseases. However, the specific mechanisms and signaling pathways of immunosenescence and inflammaging in the context of aging-associated cardiovascular diseases have yet to be fully understood.
This Research Topic aims to address these gaps by collecting original research papers and reviews that explore the physiological and biological aspects of cardiovascular diseases associated with aging in relation to immunosenescence and inflammaging. We encourage submissions that focus on the following issues, while also considering related topics:
- Inflammaging and its association with cardiovascular diseases.
- The involvement of immune exhaustion in the dysregulation of cardiovascular function in aging.
- Molecular pathways underlying the control of cell senescence in age-associated cardiovascular diseases.
- Profiling immune responses in the inflammaging process.
- Exploring the proteomics and metabolomics profiles characteristic of inflammation and immunosenescence, specifically in the context of cardiovascular aging and pathology.
By shedding light on these areas, we seek to deepen our understanding of the intricate interplay between aging, immunosenescence, inflammaging, and cardiovascular diseases.
Keywords: inflammaging, immunosenescence, cardiovascular disease
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.